Main Category: Prostate / Prostate Cancer
Also Included In: Radiology / Nuclear Medicine
Article Date: 28 Jun 2012 - 1:00 PDT
email to a friend  
printer friendly  
opinions  <!-- 
rate article 
Patient / Public:
Healthcare Prof: A recent Phase I/II clinical trial has shown that a new combination of radiation therapies developed at Virginia Commonwealth University Massey Cancer Center escalates radiation doses to safely and effectively treat prostate cancer and lower the risk of recurrence with minimal radiation exposure to nearby healthy tissue and organs.
Recently published in the journal Brachytherapy, a novel treatment protocol designed by Michael Hagan, M.D., Ph.D., radiation oncologist at VCU Massey Cancer Center, that combines intensity-modulated radiation therapy with high-dose rate (HDR) brachytherapy was tested on 26 prostate cancer patients. Intensity-modulated radiation therapy uses computer-controlled linear accelerators to modulate the intensity of an external radiation beam to more accurately deliver radiation to tumors. HDR brachytherapy is an internal form of radiation therapy that uses small radioactive pellets implanted near the tumor.
"Recent studies have shown that both higher daily doses and higher total doses of radiation are better than standard doses in controlling prostate cancer, but these higher doses may be associated with higher rates of bladder and bowel complications," says the study's lead author Mitchell Anscher, M.D., Florence and Hyman Meyers Chair of Radiation Oncology and program co-leader of Radiation Biology and Oncology at VCU Massey Cancer Center. "Our study was designed to reduce radiation exposure to nearby healthy tissue and organs and we were pleased to find that this unique dosing schedule is safe and effective."
The toxicity of the therapy was relatively low and all 26 patients were able to complete treatment. The treatment required only one HDR brachytherapy implant, and all participants were treated as outpatients. After 4.5 years, none of the patients relapsed and the rate of long-term side effects was low.
"Our goal is to improve outcomes for our patients, so we are continually researching ways to reduce unnecessary radiation exposure to healthy tissues and make treatments shorter and more manageable. We're hopeful our findings will lead to better tumor control rates and fewer complications for men with prostate cancer," says Anscher.
Moving forward, the researchers plan to continue exploring prostate cancer therapies using higher dose rates and shorter treatment times. The next step will likely be a four-treatment study utilizing stereotactic body radiosurgery, a technique popular with brain cancer that provides higher accuracy and requires fewer treatments by focusing high-powered X-rays on a very small area.
- Additional
- References
- Citations
View the full manuscript of this study at: http://www.sciencedirect.com/science/article/pii/S1538472111003564
This study was supported, in part, with funding from VCU Massey Cancer Center's NIH-NCI Cancer Center Support Grant P30 CA016059.
Virginia Commonwealth University Please use one of the following formats to cite this article in your essay, paper or report:
MLA
APA
Please note: If no author information is provided, the source is cited instead.
Add Your Opinion On This Article
'Safely Treating Prostate Cancer And Lowering The Risk Of Recurrence'Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.
If you write about specific medications or operations, please do not name health care professionals by name.
All opinions are moderated before being included (to stop spam)
Contact Our News Editors
For any corrections of factual information, or to contact the editors please use our feedback form.
Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.
Privacy Policy | Terms and Conditions
MediLexicon International Ltd
Bexhill-on-Sea, United Kingdom
MediLexicon International Ltd © 2004-2012 All rights reserved.
MNT (logo) is the registered EU trade mark of MediLexicon Int. Limited.
back to top | home | privacy policy
MediLexicon International LtdBexhill-on-Sea, United Kingdom
MediLexicon International Ltd © 2004-2012 All rights reserved.
MNT (logo) is the registered EU trade mark of MediLexicon Int. Limited.
Tidak ada komentar:
Posting Komentar